Nykode Therapeutics AS (CHIX:NYKDo)
kr 18.69 0 (0%) Market Cap: 2.06 Bil Enterprise Value: 666.43 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 57/100

Nykode Therapeutics ASA at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 02:00PM GMT
Michael Engsig
Nykode Therapeutics ASA - CEO

And welcome to this presentation by Nykode, and thanks to Jefferies team for hosting us. Once again, always a pleasure to be back. Today, we're going to take you through a short introduction to the company, the technology, and a deeper look at the very positive data released from our Phase 2 trial C-02 with VB10.16, our lead and lead candidate.

Just a quick look at our forward-looking statements. We assume you're all familiar with those. And on that note, we'll skip for the next slide.

So this slide is just a tee up for those of you who are new to the story of Nykode. Nykode is a clinical-stage immunotherapy company entirely focused on exploring our immune therapy platform, which in one sentence uniquely targets the antigens to the antigen-presenting cells, which in turn generates a strong and broad CD8 T cell response, which we've shown to be correlated to clinical outcome across solid tumors.

The technology platform is modular in its design, which means we can easily adapt the antigens to new tumor types. We can take it into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot